Cargando…

CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo

PURPOSE: In previous research, we have found that LMP1-specific chimeric antigen (HELA/CAR) T cells can specifically recognize and kill LMP1-positive NPC cells. However, the tumor-inhibitory effectiveness of HELA/CART cells needs to be enhanced. METHODS: We created two CARs that contain the T cell r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Xiaojun, Tang, Qi, Mao, Yuan, Huang, Xiaochen, Jia, Lizhou, Zhu, Jin, Feng, Zhenqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6847990/ https://www.ncbi.nlm.nih.gov/pubmed/31807014 http://dx.doi.org/10.2147/OTT.S221040

Ejemplares similares

T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo
por: Tang, Xiaojun, et al.
Publicado: (2014)

c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo
por: Huang, Xiaochen, et al.
Publicado: (2022)

MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
por: Mao, Yuan, et al.
Publicado: (2019)

CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer
por: Yi, Ling, et al.
Publicado: (2022)

CD137 Expression Is Induced by Epstein-Barr Virus Infection through LMP1 in T or NK Cells and Mediates Survival Promoting Signals
por: Yoshimori, Mayumi, et al.
Publicado: (2014)

Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo
por: Sommermeyer, Daniel, et al.
Publicado: (2015)

CD137-CD137 Ligand Interactions in Inflammation
por: Kwon, Byungsuk
Publicado: (2009)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2015)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2016)

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33(+) Acute Myeloid Leukemia
por: Dutour, A., et al.
Publicado: (2012)

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
por: Zhang, Yajun, et al.
Publicado: (2021)

Preparation and Evaluation of Human-Murine Chimeric Antibody against Protective Antigen of Bacillus anthracis
por: Hao, Lina, et al.
Publicado: (2014)

Programmed death‐ligand 1 expression on CD22‐specific chimeric antigen receptor‐modified T cells weakens antitumor potential
por: Liu, Jie, et al.
Publicado: (2022)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015)

In vivo and in vitro study of co-expression of LMP1 and Cripto-1 in nasopharyngeal carcinoma()
por: Ye, Qing, et al.
Publicado: (2019)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Ex vivo enrichment of PRAME antigen‐specific T cells for adoptive immunotherapy using CD137 activation marker selection
por: Lee, Koon H, et al.
Publicado: (2020)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

Measurement of CD8(+) and CD4(+) T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs
por: Sohn, Dae-Hee, et al.
Publicado: (2015)

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma
por: Ogunnaike, Edikan A., et al.
Publicado: (2021)

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
por: Wang, Yan, et al.
Publicado: (2023)

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
por: Bolaños-Mateo, Elixabet, et al.
Publicado: (2014)

Generating CTLs against the subdominant EBV LMP antigens by transit expression of an A20 inhibitor with EBV LMP proteins in human DCs
por: Hong, Bangxing, et al.
Publicado: (2011)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?
por: Kwon, Byungsuk
Publicado: (2015)

Correction: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Publicado: (2023)

Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
por: Adler, Adam J., et al.
Publicado: (2013)

CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives
por: Zeng, Qun, et al.
Publicado: (2019)

Evaluation of Nonviral piggyBac and lentiviral Vector in Functions of CD19chimeric Antigen Receptor T Cells and Their Antitumor Activity for CD19(+) Tumor Cells
por: Lin, Zhicai, et al.
Publicado: (2022)

Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
por: Luu, Khang, et al.
Publicado: (2021)

The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity
por: Choi, Beom K., et al.
Publicado: (2020)

Increased Soluble CD137 Levels and CD4+ T‐Cell‐Associated Expression of CD137 in Acute Atherothrombotic Stroke
por: He, Yang, et al.
Publicado: (2018)

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
por: Alvarez‐Fernández, Carmen, et al.
Publicado: (2021)

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
Publicado: (2022)

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
por: Bella, Ángela, et al.
Publicado: (2022)

Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012)

Reduced Expression of the Antigen Processing Machinery Components TAP2, LMP2, and LMP7 in Tonsillar and Base of Tongue Cancer and Implications for Clinical Outcome()
por: Tertipis, Nikolaos, et al.
Publicado: (2015)

The Roles of CD137 Signaling in Atherosclerosis
por: Jung, In-Hyuk, et al.
Publicado: (2016)

Epstein-Barr Virus LMP1 Modulates the CD63 Interactome
por: Cheerathodi, Mujeeb, et al.
Publicado: (2021)

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
por: Li, Ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2nlk0qo5vinjkava1lssqdegkv